AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06444295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity scheduling
Description: Participants will engage in activity scheduling in the app (i.e., Activities module). On the first day of using the app, users will create a list of valued/important and avoided activities (e.g., spending time with friends, going to the gym), and then have the option to add alcohol protective behavioral strategies (e.g., adding ice to drinks, alternating alcoholic and nonalcoholic beverages) to activities that the user identifies as being likely to involve drinking. On subsequent days, users will be encouraged to complete at least one activity from their list.
Study NCT06444295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Description: Participants will engage in cognitive restructuring in the app (i.e., Thoughts activities). Users first go through an activity involving the identification of maladaptive cognitions and create a list of their maladaptive cognitions. On subsequent days, they engage in a guided in-app activity involving cognitive restructuring of maladaptive cognitions from their list.
Study NCT06444295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching calls
Description: Participants will receive 10-20 minute weekly coaching calls during the app use period (4 total, including coaching provided in the enrollment call). All coaching calls will, at minimum, include a check-in, troubleshooting of technical issues, check-in about experience with symptom self-monitoring, and offers of referrals. Coaching calls in conditions involving activity scheduling will involve assistance with the Activities module. Coaching calls in conditions involving cognitive restructuring will involve assistance with the Thoughts module.
Study NCT06444295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-core intervention components
Description: All participants, regardless of condition, will receive the following non-core THRIVE components.~* 21 days of brief self-report surveys in the app assessing their PTSD symptoms and alcohol use in the prior 24 hours.~* A banner in their app displaying rotating non-personalized encouraging messages from other users. All app users will have the option of submitting encouraging statements to be displayed to all other users. Statements will be vetted by study staff before posting.~* Lists of referral options specific to each recruitment site via the Resources section of the app.~* Answers to frequently asked questions about the study, the study consent form, and contact information for the study team via the Information section of the app.~* One call with a study point person within the first week following randomization to ensure they were able to access the app and troubleshoot access issues
Study NCT06444295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-core intervention components
Description: All participants, regardless of condition, will receive the following non-core THRIVE components.~* 21 days of brief self-report surveys in the app assessing their PTSD symptoms and alcohol use in the prior 24 hours.~* A banner in their app displaying rotating non-personalized encouraging messages from other users. All app users will have the option of submitting encouraging statements to be displayed to all other users. Statements will be vetted by study staff before posting.~* Lists of referral options specific to each recruitment site via the Resources section of the app.~* Answers to frequently asked questions about the study, the study consent form, and contact information for the study team via the Information section of the app.~* One call with a study point person within the first week following randomization to ensure they were able to access the app and troubleshoot access issues
Study NCT04011579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSFIT
Description: MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
Study NCT05272670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A digital foot self-management program
Description: A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Hydrochloride 10 MG/ML
Description: Nalbuphine(10mg/ml) 0.8 mg intrathecal
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9 % in 5 ML Injection
Description: 0.9% Sodium Chloride 0.08 ml intrathecal
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride, Spinal
Description: 0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride, Spinal
Description: 0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalbuphine Hcl 10Mg/Ml Inj
Description: 4 mg IV prn for postoperative pain score>=4 q 6 h
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Hcl 10Mg/Ml Inj
Description: 4 mg IV prn for postoperative pain score>=4 q 6 h
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen 500Mg Tab
Description: 1 tab oral prn for postoperative pain score 1-3 q 6 h
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: 1 tab oral prn for postoperative pain score 1-3 q 6 h
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8mg
Description: 8 mg IV prn for nausea or vomiting q 8 h
Study NCT06153602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: 8 mg IV prn for nausea or vomiting q 8 h
Study NCT05127798 — intervention group
Intervention type: OTHER
Intervention: Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.
Description: Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
Study NCT05221346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant food supplement
Description: Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
Study NCT05221346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
Study NCT05269303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Live With Wearable Monitoring Device program
Description: The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
Study NCT05610943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided quadratus lumborum nerve block
Description: The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
Study NCT05610943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block
Description: The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
Study NCT04756570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
Study NCT04756570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Group 1
Description: Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
Study NCT04756570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Group 2
Description: Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
Study NCT05420922 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib Oral Product
Description: Lenvatinib or Sorafenib
Study NCT05420922 — intervention group
Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
Study NCT05420922 — intervention group
Intervention type: PROCEDURE
Intervention: Local treatment
Description: Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
Study NCT05585138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: segmental breathing exercise
Description: Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
Study NCT05764538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Study NCT05585138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing
Description: conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
Study NCT05585138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep breathing
Description: conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
Study NCT05095363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCplanner
Description: A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
Study NCT05643820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 5% topical lotion
Description: patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
Study NCT05643820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
Study NCT05876611 — intervention group
Intervention type: DEVICE
Intervention: New type of self stabilizing atlantoaxial fusion cage
Description: Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
Study NCT06645574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.
Description: Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires
Study NCT06647212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: introducing breathing exercises with the harmonica
Description: In addition to regular breathing exercises, participants will perform harmonica exercises
Study NCT06645769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: will be compared to placebo
Study NCT06645769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will be compared to NaPB
Study NCT05096468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine and pregabalin
Description: * Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Study NCT05096468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline and placebo capsule
Description: * Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours
Study NCT06000982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTCY
Description: PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
Study NCT06000982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTCY
Description: PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
Study NCT05232474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KomPas+
Description: KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.
Study NCT05232474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: KomPas
Description: KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
Study NCT05232474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KomPas
Description: KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as SC injection.
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab will be administered as SC injection.
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered as SC injection.
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously (IV).
Study NCT05552222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as SC injection.
Study NCT06382909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory level
Description: Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage
Study NCT06382909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inflammatory level
Description: Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage
Study NCT06382909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive assessment
Description: Neurological assessment Psychiatric assessment
Study NCT06382909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive assessment
Description: Neurological assessment Psychiatric assessment
Study NCT06382909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pedagogical assessment
Description: Sociopedagogical assessment
Study NCT06382909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pedagogical assessment
Description: Sociopedagogical assessment
Study NCT06512103 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Apical periodontitis group
Description: Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient
Study NCT04297618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiidra
Description: Xiidra (lifitegrast 5% ophthalmic solution)
Study NCT06619730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedline Brain Function Monitor
Description: The anesthesia provider will use the Sedline Brain Function Monitor information to affect their anesthetic dosing.
Study NCT06617104 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06618105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Description: Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)
Study NCT06618105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Placebo
Description: Matching Placebo of T inhalation aerosol
Study NCT06618105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Placebo
Description: Matching Placebo of T inhalation aerosol